Breast-cancer checks could begin as young as 30 to catch disease early
Women could be offered breast-cancer checks from the age of 30 under a new approach being trialled by the NHS.
Early findings show almost one in five of those in their 30s have significantly increased risks of breast cancer, the most common cause of death in young women.
Every year, more than 10,000 women in the UK who are too young to be offered screening are diagnosed with the disease, with 2,000 deaths among those below the age of 50.The study is being led by a consultant at the world-renowned Christie hospital in Manchester, which treated Sarah Harding, the Girls Aloud singer, who died from breast cancer aged 39. Dr Sacha Howell, the lead oncologist on the study, said that in future, all women should undergo 'comprehensive risk assessment' from the age of 30.
This would mean DNA tests and health questionnaires as a minimum, with annual mammograms for some and lifestyle advice for all.
Currently, NHS breast-cancer screening normally starts at age 50, but around one in three women do not come forward for checks.
Ms Harding's former bandmates said the findings were 'astounding' and that the singer, who died in 2021, would have been 'thrilled' that her legacy was making such a difference.
The Breast Cancer Risk Assessment in Young Women (Bcan-Ray) study has tested more than 700 women aged 30 to 39 so far, and aims to recruit 1,000 by the end of June.
The research will compare 750 women who have not had breast cancer and have no strong family history of the disease, with 250 women who have already been diagnosed with breast cancer.
The research is being expanded to other hospitals as NHS officials work on a national cancer plan, which will have the aim of speeding up diagnosis and treatment.
Under the new model, every participant receives a low-dose assessment mammogram, completes a detailed questionnaire, and provides a saliva sample for genetic testing.
The team works with scientists from Cambridge University to calculate each woman's personalised breast-cancer risk score.
On Saturday, Dr Howell will chair a panel on prevention, risk reduction and genetics at a cancer conference hosted by the American Society of Clinical Oncology in Chicago.
Speaking ahead of the event, the oncologist said: 'Breast cancer is the most common cause of death in women aged 35 to 50 in this country and about two-thirds of women who develop breast cancer don't have a family history of it.
'What we want to do is to try and identify women at increased risk so that we can start screening early and reduce the chances of these women dying.'
Dr Howell added: 'I would like all women over 30 to have a breast-cancer risk assessment; that doesn't have to be a mammogram, probably the most powerful part of this is the DNA analysis.'
The study is one of the first in the world to identify new ways to predict the risk of younger women getting breast cancer.
So far, of the 548 cases analysed, 104 – or 19 per cent – were identified as higher-than-average risk.
These are now being offered tailored health advice, including how to cut their risk of cancer through diet and exercise, with annual mammograms scheduled once they cross risk thresholds.
The definition of 'higher risk' means a 3 per cent chance of developing breast cancer in the next 10 years. This is the average risk for a woman aged 50 and over, which is why mammograms are offered routinely then.
The study is the first of its kind for young women, helping to identify those more at risk to offer breast surveillance to detect cancers earlier, when treatment is more likely to be successful.
The research is being funded by the Christie Charity's Sarah Harding Breast Cancer Appeal, and contributions from her family and former bandmates.
Dr Howell said the singer had spoken to him many times about 'wanting to leave a legacy for future women'.
The appeal was initiated by the Christie Charity in collaboration with the singer's family, friends, and her Girls Aloud bandmates: Cheryl Tweedy, Kimberley Walsh, Nadine Coyle, and Nicola Roberts.
They said: 'We are so pleased about the progress of the Bcan-Ray study and know that Sarah would be thrilled.
'To hear that women who had no idea they could be at risk of breast cancer are being identified and able to take preventative measures is astounding.
'This study in Sarah's name has the potential to be life saving and we are hopeful the results will be rolled out across the UK allowing doctors to predict and prevent breast cancer for many women. Sarah was an amazing woman and we couldn't be more proud of the legacy she has left.'
Together, the appeal, which is also backed by Ms Harding's family and friends, has raised over £1 million for breast-cancer research.
Around 2,300 women aged 39 and under are diagnosed with breast cancer in the UK each year.
The programme began in the Christie hospital but is being expanded to other NHS cancer units across the UK, including units in Lancaster, Wirral, Bolton, Tameside, Leighton, Wigan and Macclesfield.
Results are expected to be published next year, and fed into the UK national screening committee, after which trials may be rolled out more widely.
It will see how far breast density is a risk factor in younger women, who are known to often have more dense breasts, but are rarely screened. Women with dense breasts are four times more likely to develop breast cancer, but tissue can also mask tumours on a mammogram, making disease harder to spot.
Separate research will compare different methods, to see whether mammograms are required to check breast density.
Breast screening is routinely offered to women aged 50 and over, but millions of women miss out on mammograms, with around one third failing to come forward. Programmes saw a significant dip in uptake during the pandemic, with services closed during the first lockdown.
Simon Vincent, director of research, support and influencing at charity Breast Cancer Now, said: 'While breast cancer is less common in younger women, it's a leading cause of death in women aged under 50.
'Around 2,400 women aged 39 or under hear the words 'you have breast cancer' each year in the UK, and this is why ongoing research, like Bcan-Ray, plays a vital role in helping us to further understand breast-cancer risk in younger women and, importantly, whether the introduction of risk-based screening or screening at a younger age could save more lives from the disease.'
He said the upcoming national cancer plan for England 'presents a critical opportunity to focus on improving access to risk-reduction treatment and early diagnosis tools, that can ultimately help reduce deaths from breast cancer'.
Prof Peter Johnson, NHS national clinical director for cancer, said: 'We are working closely with the Government on a national cancer plan to ensure the NHS continues to deliver progress in diagnosing more cancers earlier and saving lives, and this research provides valuable information about the potential for more personalised approaches to screening.
'If women are worried about any symptoms, whatever their age, or if they notice a change in their bodies or something that's unusual for them, then I would encourage them to contact their GP.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Pharmacists warn drug shortage affecting cancer patients
Pharmacists have warned that "one of the worst" examples of medicine shortages is affecting cancer patients. Creon, a pancreatic enzyme replacement therapy (Pert), helps digestion and is required by patients with pancreatic cancer, cystic fibrosis, and chronic pancreatitis. It is thought more than 61,000 patients in the UK need the medicine. Some patients are said to be "skipping meals" to ration their medication due to a shortage of it, according to the National Pharmacy Association (NPA). A Department of Health and Social Care spokesperson said there were "European-wide supply issues" and it was "working closely with industry and the NHS" to mitigate the impact on patients. Without the drug, patients lose weight and strength, which means their ability to cope with treatment such as chemotherapy is reduced. Some experts have predicted shortages continuing until next year. The Department of Health and Social Care has extended a serious shortage protocol for Creon which has already been in place for a year. This indicates concern about shortages of a medicine and allows pharmacists to give patients an alternative - though they argue other drugs are also in short supply. A spokesperson for the department said the "European-wide supply issues" were caused by manufacturing supply constraints. The National Pharmacy Association said more than three quarters of members covered in a recent survey felt the current arrangements for managing the shortages were inadequate. Some reported that patients were skipping meals and travelling long distances to get hold of the medication, according to the NPA. One said it was the "worst stock shortage" they had ever had to deal with. BBC News highlighted the issue in February after a woman got in touch saying it was impossible for her husband, who has pancreatic cancer, to digest his food without Creon. That month, leading pancreatic clinicians and charities wrote to the prime minister, saying the absence of Pert can have a "devastating impact on people's lives". They called for a national strategy to tackle the shortage. Alice from Birmingham was diagnosed with pancreatic cancer in 2023 and initially got 15 boxes of Creon capsules every month to help her tolerate chemotherapy. She can now get only six or seven and is having to skip snacks. The 64-year-old said the shortage had profoundly affected her mental health. She told the BBC: "Each day I'm trying to balance: what shall I eat, shall I have a more substantial meal, shall I take my supplements and that creates an extra layer of stress and worry whilst I'm trying to put my life together again after having this diagnosis." Alfie Bailey-Bearfield of Pancreatic Cancer UK said the charity had been raising concerns with the government and suppliers for more than a year and it was vital that officials intervened to try to boost supply. "Thousands of people affected by pancreatic cancer rely on taking Pert tablets every time they eat simply to digest their food and absorb nutrients – something most of us take for granted," he said. "It's totally unacceptable that they are still taking desperate measures which puts their health, wellbeing and their eligibility for treatment at risk," he added. Dr Leyla Hannbeck, chief executive of the Independent Pharmacies Association said it was very difficult for her members to obtain supplies from the wholesaler. "The shortages with Creon has been ongoing for so long and it seems no effective attempts are being made by officials to make the process easier for pharmacies and patients and to put robust plans in place to prioritise the availability of this product," she said. "Instead they continue prolonging the current processes." A Department of Health and Social Care spokesperson said it knew "how frustrating and distressing" medicine supply issues can be for patients and clinicians caring for them. They added: "The European-wide supply issues with Creon are caused by a limited availability of raw ingredients and manufacturing capacity constraints. "We are working closely with industry and the NHS to mitigate the impact on patients and resolve the issues as quickly as possible." Cancer patients 'may starve' without vital drug
Yahoo
17 hours ago
- Yahoo
Chris Hoy cancer battle leads to referral spike
Sir Chris Hoy's cancer diagnosis has led to an increase in referrals - and subsequent treatment backlogs - at a Devon hospital, figures have revealed. A performance report presented to the University Hospitals Plymouth (UHP) NHS Trust Board said there had been a 55% rise in prostate cancer referrals since November last year. In October, six-time Olympic cycling champion Sir Chris revealed that doctors had told him his prostate cancer was terminal. The report said UHP had a backlog of cancer patients waiting for treatment following a referral and the awareness raised by Sir Chris was one of the "key existing challenges" behind the issue. NHS targets state patients should wait no more than 62 days between the date a hospital receives an urgent suspected cancer referral and the start of treatment. Trusts are expected to meet this standard in 85% of cases, the Local Democracy Reporting Service (LDRS) said. UHP's board was told 118 urology patients were waiting more than 62 days in April - 46 more than the previous year - and 36 had waited more than 104 days. The board was also told UHP fell short in April of the national requirement and its own improvement plan to communicate a diagnosis to patients with suspected cancer within 28 days. "The key existing challenge was urology with a 55% increase in referrals from November 2024 following the publicity around the diagnosis of Sir Chris Hoy," a report from UHP's chief operating officer Jo Beer said. The report added clinic space at the skin cancer unit was now "insufficient" following years of growth in demand. An urgent piece of work was under way to assess sites which could enable expansion in order to diagnose patients in the expected time frame, the report said. The figures showing more prostate cancer referrals at Derriford Hospital were described as welcoming news by The Chestnut Appeal for Men's Health. The Derriford Hospital-based charity, which supports men diagnosed with prostate, testicular and penile cancer, said Sir Chris's diagnosis had led to a significant increase in testing and referrals across the UK. Chief executive Lesley-Ann Simpson added issues did still remain around diagnosing prostate cancer as there was "no simple test" to detect it and demand for the charity's services was growing. "Trials are on going for more simpler and accurate tests, such as a saliva test, which could release the burden on hospitals," Ms Simpson said. "Until that time, charities like ours are also experiencing increasing demands for our services, and requests for support, whilst donations are in a decline." Follow BBC Cornwall on X, Facebook and Instagram. Follow BBC Devon on X, Facebook and Instagram. Send your story ideas to spotlight@ More cancer referrals after Sir Chris Hoy diagnosis Chris Hoy says raising cancer awareness gives him purpose Cyclist Sir Chris Hoy announces his cancer is terminal NHS - Prostate Cancer The Chestnut Appeal for Men's Health University Hospitals Plymouth NHS Trust Board

Yahoo
18 hours ago
- Yahoo
NHS surgeon who compared Islam to Nazism struck off
An NHS surgeon, who claimed he had been discriminated against at work, has been struck off for anti-Islamic posts comparing the religion to Nazism. Dr Keyur Buch also shared a post on X that claimed '99.8 per cent of terrorists across the world are Muslims'. The surgeon, currently based in Ahmedabad, India, was initially suspended from the register for just four months over the 'racially and religiously hostile' posts. A review panel has now found that the surgeon had 'persistently failed' to show insight into his actions and decided to strike Dr Buch from the General Medical Council (GMC) register. The medical practitioners tribunal reviewing his case heard that Dr Buch qualified in India in 1987 before moving to the UK in 1995. He left the country in 2016 but has remained on the GMC register. In July 2022 he gave an interview to a UK-based Asian newspaper alleging that a colleague had once told him he would 'never hire a brown person' and that the NHS was 'institutionally racist'. He was first reported for his 'hostile' posts in September 2022 by a fellow doctor and two members of the public, shortly after they were published. Dr Buch was initially suspended for four months following a hearing in 2023. The suspension was then extended by a further 12 months in April 2024. The review panel has now decided to strike Dr Buch off entirely, saying: 'A sanction of erasure was the only sanction that would address Dr Buch's persistent failure to demonstrate insight. 'The tribunal was satisfied that there was a lack of meaningful engagement from Dr Buch, and he had failed to demonstrate adequate development of insight or any remediation in the 16 months since he was suspended.' The 2023 hearing was told that the medical professional had made several inappropriate posts on an X account under the name 'Dr Keyur Buch | Consultant Orthopedic Surgeon'. In one of his posts he said: 'Just like Nazism and Communism, I5lam is a supremacist violent cult that needs to be got rid of because it harms Mu5lims and nonMus1ims alike.' Dr Buch also used the hashtag '#IslamIsTheProblem', linked 'Muslim schools' with 'Islamic terrorists' and referred to the Prophet Muhammad as 'MohMad'. In another post the surgeon claimed there was an 'invasion' of Pakistani Muslims on Hindus in the UK. Screenshots of his social media posts were sent to the GMC by a doctor and two members of the public who said they 'incited hate towards Muslims'. Dr Buch told the tribunal he 'acknowledged the upset and hurt caused' by his posts and claimed they were 'provoked' by the Leicester riots taking place at the time. He said the unrest between British Muslims and Hindus in the Midlands city, sparked by a cricket match, was 'personal' because a temple he used to visit in Leicester was attacked. He also said his account had been 'hacked' and the posts were written by others. The 2023 panel found the 'offensive nature' of the surgeon's statements had 'undermined' the integrity of doctors. They suggested he could assist future reviews by showing that he had taken steps to 'better understand' equality and diversity. The panel said: 'The offensive nature of Dr Buch's social media posts, irrespective of whether he felt at the time that they were provoked by emotive national events, were made to a significant audience and could be directly linked to his profession as an orthopaedic surgeon. 'Doctors, in all aspects of their lives, are expected to act with integrity to ensure that public trust in the medical profession is maintained. 'Dr Buch's actions undermined that.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.